Leukopenia and lack of ribavirin predict poor outcomes in patients with haematological malignancies and respiratory syncytial virus infection

Medicine and Dentistry

• Respiratory Syncytial Virus Infection 100%
• Patient 100%
• Hematologic Malignancy 80%
• Lower Respiratory Tract Infection 80%
• Human Respiratory Syncytial Virus 80%
• Ribavirin 60%
• Upper Respiratory Tract Infection 60%
• Diagnosis 40%
• Neutropenia 40%
• Lymphocytopenia 40%
• Inpatient 40%
• Morbidity 20%
• Infection Rate 20%
• Regression Analysis 20%
• Malignant Neoplasm 20%
• Multiple Myeloma 20%
• Combination Therapy 20%
• Mortality Rate 20%
• Immune Deficiency 20%
• Infection 20%
• Hodgkin's Lymphoma 20%
• Non-Hodgkin Lymphoma 20%
• Leukopenia 20%
• Patient Population 20%
• Myelodysplastic Syndrome 20%
• Mortality 20%
• Therapeutic Procedure 20%
• Chronic Myelogenous Leukemia 20%
• Acute Myelogenous Leukemia 20%
• Chronic Lymphocytic Leukemia 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Respiratory Syncytial Virus Infection 100%
• Hematologic Malignancy 80%
• Human Respiratory Syncytial Virus 80%
• Lower Respiratory Tract Infection 80%
• Ribavirin 60%
• Upper Respiratory Tract Infection 60%
• Neutropenia 40%
• Lymphocytopenia 40%
• Death 40%
• Hodgkin Disease 20%
• Multiple Myeloma 20%
• Morbidity 20%
• Nonhodgkin Lymphoma 20%
• Leukopenia 20%
• Infection 20%
• Myelodysplastic Syndrome 20%
• Immune Deficiency 20%
• Mortality Rate 20%
• Malignant Neoplasm 20%
• Infection Rate 20%
• Mortality 20%

Immunology and Microbiology

• Respiratory Syncytial Virus Infection 100%
• Lower Respiratory Tract 80%
• Human Respiratory Syncytial Virus 80%
• Upper Respiratory Tract 60%
• Ribavirin 60%
• Lymphocytopenia 40%
• Multiple Myeloma 20%
• Immunodeficiency 20%
• Morbidity 20%
• Mortality Rate 20%
• Infection Rate 20%
• Mortality 20%